BACKGROUNDS: Based on in vitro data and results of a recent drug repositioning study, some medications approved by the FDA for the treatment of various non-malignant disorders were demonstrated to have anti- @entity151 activity in preclinical models. The aim of our study is to confirm whether use of these medications is associated with survival benefit. METHODS: Consecutive @entity1 with pathologically confirmed, stage 4 @entity151 were analyzed in this retrospective study. @entity1 that were prescribed @entity6817 , @entity117 , @entity8991 ( @entity70058 ; @entity2974 ), selective @entity750 reuptake inhibitors (SSRIs), @entity16427 or @entity3159 (a1-adrenergic receptor antagonists; @entity11113 ) were identified. RESULTS: There were a total of 876 @entity1 . @entity117 , @entity6817 , SSRIs, @entity11113 , and @entity2974 were administered in 138, 72, 20, 28, and 5 cases, respectively. A statistically significant increase in median OS was observed only in @entity6817 -treated @entity1 when compared to those not receiving any of the aforementioned medications (OS, 8.4 vs. 6.1 months, respectively; p = 0.002). The administration of SSRIs, @entity117 , and @entity11113 did not result in a statistically significant OS benefit (median OS, 8.5, 6.8, and 6.0 months, respectively). The multivariate Cox model showed that, besides age and ECOG PS, radiotherapy was an independent survival predictor (Hazard Ratio, 2.151; 95% confidence interval, 1.828-2.525; p <0.001). CONCLUSIONS: Results of drug repositioning studies using only preclinical data or small numbers of @entity1 should be treated with caution before application in the clinic. Our data demonstrated that radiotherapy appears to be an independent survival predictor in stage 4 @entity151 , therefore confirming the results of other prospective and retrospective studies.

From Bench to Bedside: Attempt to Evaluate Repositioning of Drugs in the Treatment of Metastatic @entity151 ( XXXX ).

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity8991 :: ('MESH:D002997', 'Chemical') :: ['clomipramine'] @entity117 :: ('MESH:D001241', 'Chemical') :: ['Aspirin', 'aspirin'] @entity2974 :: ('CHEBI:30956', 'Chemical') :: ['TCA'] @entity70058 :: ('CHEBI:36809', 'Chemical') :: ['tricyclic antidepressant'] @entity16427 :: ('MESH:D017292', 'Chemical') :: ['doxazosin'] @entity750 :: ('MESH:D012701', 'Chemical') :: ['serotonin'] @entity11113 :: ('147', 'Gene') :: ['ADRA1'] @entity3159 :: ('MESH:D011224', 'Chemical') :: ['prazosin'] @entity151 :: ('MESH:D055752', 'Disease') :: ['SCLC'] @entity6817 :: ('D019821', 'Chemical') :: ['statin', 'statins']
@entity151 :: (MESH:D055752,Disease) :: ['SCLC']
